References in bold are published by MATHEC members
References in italics are to mesenchymal stromal cells.
2024
Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity
Tesfagiorgis Y, Kemal E A, Craig H C, Parham K A, Kerfoot S M
J Neuroimmunol. 2024 Feb 15:387:578267. doi: 10.1016/j.jneuroim.2023.578267. Epub 2023 Dec 15.10.1016/j.jneuroim.2023.578267
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis
Mariottini A, Nozzoli C, Carli I, Landi F, Gigli V, Repice A M, Ipponi A, Cecchi M, Boncompagni R, Saccardi R, Massacesi L
Neurol Sci. 2024 Jan 26. doi: 10.1007/s10072-024-07308-y. Online ahead of print.
Successful Autologous Hematopoietic Stem Cell Transplant in Glycine Receptor Antibody-Positive Stiff Person Syndrome
Celli S I, Nash R, Money K M, Garza M, Borko T L, Mizenko C, McMenamin C, Von Geldern G, Georges G, Piquet A L
Neurol Neuroimmunol Neuroinflamm. 2024 Mar; 11(2): e200197.Published online 2024 Jan 3. doi: 10.1212/NXI.0000000000200197
2023
Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life
Braun B, Fischbach F, Richter J, Pfeffer L K, Fay H, Reinhardt S, Friese M A, Stellmann J P, Kröger N M, Heesen C, Häußler V
Multiple Sclerosis and Related Disorders 82 (2024) 105414. Available online 27 December 2023. doi.org/10.1016/j.msard.2023.105414
Comment on: Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Sun T, Xie Q, Gu J
J Clin Neurosci. 2023 Sep:115:163. doi: 10.1016/j.jocn.2023.04.007. Epub 2023 Apr 13.
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
Silfverberg T, Zjukovskaja C, Ljungman P, Nahimi A, Ahlstrand E, Dreimane A, Einarsdottir S, Fagius J, Iacobaeus E, Hägglund H, Lange N, Lenhoff S, Lycke J, Mellergård J, Piehl F, Svenningsson A, Tolf A, Cherif H, Carlson K, Burman J
J Neurol Neurosurg Psychiatry. 2023 Sep 25:jnnp-2023-331864. doi: 10.1136/jnnp-2023-331864.
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
Bayas A, Berthele A, Blank N, Dreger P, Faissner S, Friese M A, Gerdes L-A, Grauer O M, Häussler V, Heesen Ch, Janson D, Korporal-Kuhnke M, Kowarik M, Kröger N, Lünemann J D, Martin R, Meier U, Meuth S, Muraro P, Platten M, Schirmer L, Stürner K H, Stellmann J P, Scheid C, Bergh F T, Warnke C, Wildemann B, Ziemssen T; for the Task force AHSCT of the German Multiple Sclerosis Competence Network
Ther Adv Neurol Disord. 2023; 16: 17562864231180730. Published online 2023 Sep 28. doi: 10.1177/17562864231180730
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
Silfverberg T, Zjukovskaja C, Ljungman P, Nahimi A, Ahlstrand E, Dreimane A, Einarsdottir S, Fagius J, Iacobaeus E, Hägglund H, Lange N, Lenhoff S, Lycke J, Mellergård J, Piehl F, Svenningsson A, Tolf A, Cherif H, Carlson K, Burman J
J Neurol Neurosurg Psychiatry. 2024 Feb; 95(2): 125–133.Published online 2023 Sep 25. doi: 10.1136/jnnp-2023-331864
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Kalincik T, Sharmin S, Roos I, Freedman M S, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann A K, Havrdova E K, Krasulova E, Trnený M, Kozak T, Van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury S J, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa M J, Van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden J A; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo J L, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans Koen, Kermode A; MSBase Study Group
JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184.
Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis
Zheng Y, Hu J, Sun C, Zhao C, Lin J.
Eur J Neurol. 2023 May 12. doi: 10.1111/ene.15857.
2022
Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Nabizadeh F, Masrouri S, Sharifkazemi H, Azami M, Nikfarjam M, Moghadasi A N
J Clin Neurosci. 2022 Nov:105:37-44. doi: 10.1016/j.jocn.2022.08.020. Epub 2022 Sep 6.
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Niederhäusern V, Ruder J, Ghraichy M, Jelcic I, Müller A.M, Schanz U, Martin R, Trück J
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 13;9(6):e200027.
Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus
Goklemez S, Hasni S, Hakim F T, Muraro P A, Pirsl F, Rose J, Memon S, Fowler D F, Steinberg S M, Baker E H, Panch S R, Gress R, Illei G G, Lipsky P E, Pavletic S Z
Rheumatology, Volume 61, Issue 8, August 2022, Pages 3317–3328.
Possible Effect of the use of Mesenchymal Stromal Cells in the Treatment of Autism Spectrum Disorders: A Review
Tamouza R, Volt F, Richard J-R, Wu C-L, Bouassida J, Boukouaci W, Lansiaux P, Cappelli B, Scigliuolo GM, Rafii H, Kenzey C, Mezouad E, Naamoune S, Chami L, Lejuste F, Farge D and Gluckman E
Front. Cell Dev. Biol., 05 July 2022 Sec. Stem Cell Research
Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial
Yao XY, Xie L, Cai Y, Zhang Y, Deng Y, Gao MC, Wang YS, Xu HM, Ding J, Wu YF, Zhao N, Wang Z, Song YY, Wang LP, Xie C, Li ZZ, Wan WB, Lin Y, Jin HJ, Wang K, Qiu HY, Zhuang L, Zhou Y, Jin YY, Ni LP, Yan JL, Guo Q, Xue JH, Qian BY, Guan YT
Front Neurol. 2022 Apr 25;13:860083.doi: 10.3389/fneur.2022.860083. eCollection 2022.
Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
Stokke Kvistad SA, Burman J, Lehmann AK, Tolf A, Zjukovskaja C, Melve GK, Bø L, Torkildsen O
J Neurol Neurosurg Psychiatry. 2022 Aug;93(8):844-848.doi: 10.1136/jnnp-2022-328797. Epub 2022 May 4.
Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party
Cencioni MT, Genchi A, Brittain G, de Silva T I, Sharrack B, Snowden JA, Alexander T, Greco R, Muraro PA
J Neurol. 2022; 269(7): 3937–3958.Published online 2022 Apr 11. doi: 10.1007/s00415-022-11063-5
Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party
Cencioni MT, Genchi A, Brittain G, de Silva T I, Sharrack B, Snowden JA, Alexander T, Greco R, Muraro PA
Front Immunol. 2022 Feb 1;12:813957.doi: 10.3389/fimmu.2021.813957. eCollection 2021.
Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis
Mariottini A, Bulgarini G, Forci B, Innocenti C, Mealli F, Mattei F, Ceccarelli C, Repice AM, Barilaro A, Mechi C, Saccardi R, Massacesi L
Eur J Neurol. 2022 Feb 11.doi: 10.1111/ene.15280. Online ahead of print.
Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis
Massey J, Jackson K, Singh M, Hughes B, Withers B, Ford C, Khoo M, Hendrawan K, Zaunders J, Charmeteau-De Muylder B, Cheynier R, Luciani F, Ma D, Moore J, Sutton I
Front Immunol. 2022 Feb 7;13:798300.doi: 10.3389/fimmu.2022.798300. eCollection 2022.
Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
Petrou P, Kassis I, Ginzberg A, Hallimi M, and Karussis D.
Stem Cells Transl Med. 2022 Jan; 11(1): 55–58. Published online 2022 Feb 15. doi: 10.1093/stcltm/szab017
2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Tello CR, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS, MESEMS investigators
Lancet Neurol. 2021 Nov;20(11):917-929.doi: 10.1016/S1474-4422(21)00301-X.
Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R
J Neurol. 2021 Oct 11.doi: 10.1007/s00415-021-10820-2. Online ahead of print.
A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder
Burton J M, Duggan P,Costello F, Metz L, Storek J
Mult Scler Relat Disord. 2021 Aug;53:102990.doi:10.1016/j.msard.2021.102990. Epub 2021 May 4.
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series
Nicholas R S, Rhone E E, Mariottini A, Silber E, Malik O, Singh-Curry V, Turner B, Scalfari A, Ciccarelli O, Sormani M P, Olavarria E, Mehra V, Gabriel I, Kazmi M A, Muraro P, London Group on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Neurology. 2021 Aug 31;97(9):e890-e901.doi: 10.1212/WNL.0000000000012449. Epub 2021 Jul 12.
aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
Häußler V, Ufer F, Pöttgen J, Wolschke C, Friese MA, Kröger N, Heesen C, Stellmann J-P
Ann Clin Transl Neurol. 2021 Jun;8(6):1269-1278.doi: 10.1002/acn3.51366.
Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation
Urbain F, Puyade M, Labeyrie C, Maubeuge N, Puma A, Cintas P, Pugnet G, Castilla-Llorente C, Adams D, Farge-Bancel D
J Neurol. 2021 Apr;268(4):1536-1539.doi: 10.1007/s00415-021-10452-6. Epub 2021 Mar 2.
Carrefour des spécialités : autogreffe de cellules souches hématopoïétiques périphériques pour la prise en charge thérapeutique des polyradiculonévrites inflammatoires démyélinisantes chroniquesAutologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyneuropathy
Urbain F, Labeyrie C, Castilla-Llorente C, Cintas P, Puma A, Maubeuge N, Puyade M, Farge D
https://doi.org/10.1016/j.revmed.2021.03.008
New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis
Burt RK, Muraro PA, Farge D, Oliveira MC, Snowden JA, Saccardi R, Han X, Quigley K, Bueno V, Frasca D, Fedorenko D, Burman J
Bone Marrow Transplant. 2021 Apr 28.doi: 10.1038/s41409-021-01277-y.
Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study
Albu S, Kumru H, Coll R, Vives J, Vallés M, Penalva JB, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J
Cytotherapy. 2021 Feb;23(2):146-156.doi: 10.1016/j.jcyt.2020.08.008. Epub 2020 Sep 25.
Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis
Bose G, Freedman MS
J Neurol Sci. 2021 Feb 15;421:117324.doi: 10.1016/j.jns.2021.117324.
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis
Das J , Snowden J A, Burman J, Freedman M S, Atkins H, Bowman M, Burt R K, Saccardi R, Innocenti C, Mistry S, Laud P J, Jessop H, Sharrack B
Mult Scler. 2021 Feb 10;1352458520985238.doi:10.1177/1352458520985238
Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial
Burt RK, Balabanov R, Han X, Quigley K, Arnautovic I, Helenowski I, Rose J, Siddique T
Neurology. 2021 Feb 9;96(6):e817-e830. doi: 10.1212/WNL.0000000000011338.
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Lucia M, Pia Amato M, Cottone S, Gualandi F, De Gobbi M, Greco R, Scimè R, Frau J, Bosco Zimatore G, Bertolotto A, Comi G, Uccelli A, Signori A, Angelucci E, Innocenti C, Ciceri F, Repice AM, Pia Sormani M, Saccardi R, Mancardi G, Italian BMT-MS study group
Neurology. 2021 Jan 20;10.1212/WNL.0000000000011461. doi: 10.1212/WNL.0000000000011461.
2020
Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT)
Roberts F, Hobbs H, Jessop H, Bozzolini C, Burman J, Greco R, Ismail A, Kazmi M, Kirgizov K, Mancardi G, Mawson S, Muraro P A, Puyade M, Saccardi R, Withers B, Verhoeven B, Sharrack B, Snowden J A
Front Neurol. 2020 Dec 11;11:556141.doi: 10.3389/fneur.2020.556141. eCollection 2020.
Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives
Ceglie G, Papetti L, Valeriani M, Merli P
Int J Mol Sci. 2020 Jul 26;21(15):5304.doi: 10.3390/ijms21155304.
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.>
Amoriello R , Greiff V , Aldinucci A , Bonechi E , Carnasciali A, Peruzzi B, Repice AM , Mariottini A, Saccardi R, Mazzanti B, Massacesi L, Ballerini C
Front Immunol. 2020 Apr 9;11:559.doi: 10.3389/fimmu.2020.00559.
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status
Mariottini A , De Matteis E, Muraro PA
BioDrugs. 2020 Jun;34(3):307-325.doi: 10.1007/s40259-020-00414-1.
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society
Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R, National Medical Advisory Committee of the National Multiple Sclerosis Society
JAMA Neurol. 2020 Oct 26. doi: 10.1001/jamaneurol.2020.4025.
Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis
Petrou P, Kassis I, Levin N, Friedemann P, Backner Y, Benoliel T, Cosima Oertel F, Scheel M, Hallimi M, Yaghmour N, Ben Hur T, Ginzberg A, Levy Y, Abramsky O, Karussis D
Brain 2020 December 2020. 143(12):3574–3588. https://doi.org/10.1093/brain/awaa333
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study
Zhukovsky c, Sandgren S, Silfverberg T, Einarsdottir S, Tolf A, Landtblom A-M, Novakova L, Axelsson M, Malmestrom C, Cherif H, Carlson K, Lycke J, Burman J
J Neurol Neurosurg Psychiatry. 2020 Oct 26;jnnp-2020-323992. doi: 10.1136/jnnp-2020-323992.
>Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective
Bose G, Thebault S, Rush CA, Atkins HL, Freedman M S
Mult Scler. 2020 May 4;1352458520917936. doi: 10.1177/1352458520917936. Online ahead of print.
Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis
Harris KM, Lim N, Lindau P, Robins H, Griffith L M, Nash R A, Turka L A, Muraro P A
JCI Insight. 2020 Jan 30;5(2):e127655. doi: 10.1172/jci.insight.127655.
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis
Mariottini A, Filippini S, Innocenti C, Forci B, Mechi C, Barilaro A, Fani A, Carlucci G, Saccardi R, Massacesi L, Repice A M.
Mult Scler. 2020 Feb 3;1352458520902392. doi: 10.1177/1352458520902392.
Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients
Bertolotto A, Martire S, Mirabile L, Capobianco M, De Gobbi M, Cilloni D
Neurol Ther. 2020 Dec;9(2):197-203. doi: 10.1007/s40120-020-00200-9. Epub 2020 Jun 16.
Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant
Jaime-Pérez J C, Gómez-Galaviz A C, Turrubiates-Hernández G A, Picón-Galindo E, Salazar-Riojas R, Méndez-Ramírez N, Gómez-Almaguer D
Cytotherapy. 2020 Mar;22(3):144-148. doi: 10.1016/j.jcyt.2020.01.002.
Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis
Olivares Gazca JC , Gómez Almaguer D, Gale RP, Ruiz Argüelles GJ
Hematology. 2020 Dec;25(1):320. doi: 10.1080/16078454.2020.1802931.
Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives
Ceglie G, Papetti L, Valeriani M, Merli1 P
Int J Mol Sci. 2020 Aug; 21(15): 5304.
Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy
Burt RK, Balabanov R, Tavee J, Han X, Sufit R, Ajroud-Driss S, Jovanovic B, Quigley K, Arnautovic I, Helenowski I, Sharrack B.
J Neurol. 2020 Jun 27. doi: 10.1007/s00415-020-10010-6.
Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America
Burt R K, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, Snowden JA, Hartung D
Mult Scler Relat Disord. 2020 Jul 17;45:102404.doi: 10.1016/j.msard.2020.102404.
Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis
Zhang P, Liu B
Bone Marrow Transplant. 2020 doi: 10.1038/s41409-020-0810-z.
Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review.
Sellner J, Rommer P S.
Autoimmun Rev. 2020 Apr;19(4):102492. doi: 10.1016/j.autrev.2020.102492.
Patients’ expectations of autologous hematopoietic stem cell transplantation as a treatment for MS
De Kleermaeker FGCM, Uitdehaag BMJ, van Oosten B W
Mult Scler Relat Disord. 2020 Jan;37:101467. doi: 10.1016/j.msard.2019.101467. Epub 2019 Oct 24.
2019
Autologous Hematopoietic Stem Cell Transplantation Improves Fatigue in Multiple Sclerosis
Bose G, Atkins HL, Bowman M, Freedman M S
Mult Scler. 2019 Nov;25(13):1764-1772.doi: 10.1177/1352458518802544.
Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica
Burt R K, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, Helenowski I, Jitprapaikulsan J, Fryer J P,Pittock S J
Neurology. 2019 Oct 29;93(18):e1732-e1741.doi: 10.1212/WNL.0000000000008394. Epub 2019 Oct 2.
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.
Cohen J A, Baldassari L E, Atkins H L, Bowen J D, Bredeson C, Carpenter P A, Corboy J R, Freedman M S, Griffith L M, Lowsky R, Majhail N S, Muraro P A, Nash R A, Pasquini M C, Sarantopoulos S, Savani B N, Storek J, Sullivan K M, Georges G E.
Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014.
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore J J, Massey J C, Ford C D, Khoo M L, Zaunders J J, Hendrawan K, Barnett Y, Barnett M H, Kyle K A, Zivadinov R, Ma K C, Milliken S T, Sutton I J, Ma DDF.
J Neurol Neurosurg Psychiatry. 2019 May;90(5):514-521. doi: 10.1136/jnnp-2018-319446.
Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation.
Tolf A, Fagius J, Carlson K, Åkerfeldt T, Granberg T, Larsson E M, Burman J.
Acta Neurol Scand. 2019 Nov;140(5):320-327.
Indications de l’autogreffe de cellules souches hématopoïétiques dans la polyradiculonévrite inflammatoire démyélinisante chronique : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
Puyade M, Labeyrie C, Badoglio M, Cintas P, Guenounou S, Lansiaux P, Marjanovic Z, Nicolas G, Pomies A, Terriou L, Torregrosa Diaz J M, Baron C, Castilla Llorente C, Yakoub-Agha I, Farge D.
Bull Cancer. 2019 Dec 7. pii: S0007-4551(19)30403-5.
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K, Labopin M, Mancardi G, Martin R, Moore J, Muraro PA, Rovira M, Sormani MP, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE).
Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0684-0.
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple SclerosisA Randomized Clinical Trial
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden J A, Oliveira M C, Fagius J, Rose J, Nelson F, Barreira A A, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski I B.
JAMA. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743.
Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.
Mehra V, Rhone E, Widya S, Zuckerman M, Potter V, Raj K, Kulasekararaj A, McLornan D, de Lavallade H, Benson-Quarm N, Lim C, Ware S, Sudhanva M, Malik O, Nicholas R, Muraro PA, Marsh J, Mufti GJ, Silber E, Pagliuca A, Kazmi M A.
Clin Infect Dis. 2019 Jan 15. pii: ciz047. doi: 10.1093/cid/ciz047.
Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation
Cohen J A, Baldassari L E, Atkins H L, Bowen J D, Bredeson C, Carpenter P A, Corboy J R, Freedman M S, Griffith L M, Lowsky R, Majhail N S, Muraro PA, Nash R A, Pasquini M C, Sarantopoulos S, Savani B N, Storek J, Sullivan K M, Georges G E.
Biol Blood Marrow Transplant. 2019 Feb 19. pii: S1083-8791(19)30139-9. doi: 10.1016/j.bbmt.2019.02.014
2018
Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.
Massey J C, Sutton I J, Ma DDF, Moore J J
Front Immunol. 2018 Mar 12;9:410.doi: 10.3389/fimmu.2018.00410.
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis
Harris V K, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq S A.
EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002.
[Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis].
Zephir H, Puyade M, Gueguen A, Michel L, Terriou L, Dive D, Laureys G, Mathey G, Labauge P, Marjanovic Z, Pugnet G, Badoglio M, Lansiaux P, Ibrahim YA, Béguin Y, Farge D.
Bull Cancer. 2018 Dec 4
Advising patients seeking stem cell interventions for multiple sclerosis.
von Wunster B, Bailey S, Wilkins A, Marks D I, Scolding N J, Rice C M
Pract Neurol. 2018 May 30
Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.
Darlington P J, Stopnicki B, Touil T, Doucet J S, Fawaz L, Roberts M E, Boivin M N, Arbour N, Freedman M S, Atkins H L, Bar-Or A.
Front Immunol. 2018 May 7;9:834
Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis.
Rush C A, Atkins H L, Freedman M S.
Cold Spring Harb Perspect Med. 2018 Apr 2.
Autologous haematopoietic stem cell transplantation for neurological diseases.
Burman J, Tolf A, Hägglund H, Askmark H.
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):147-155
2017
Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, Casanova B, Ouyang J, Bembeeva R, Haas J, Bader P, Snowden J, Farge D.
Bone Marrow Transplant. 2017 Aug;52(8):1133-1137
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B, Jarque I, Gascón F, Hernández-Boluda JC, Pérez-Miralles F, de la Rubia J, Alcalá C, Sanz J, Mallada J, Cervelló A, Navarré A, Carcelén-Gadea M, Boscá I, Gil-Perotin S, Solano C, Sanz MA, Coret F.
Neurol Sci. 2017 Jul;38(7):1213-1221.
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.
Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani M P, Saccardi R.
Nat Rev Neurol. 2017 Jun 16. doi: 10.1038/nrneurol.2017.81
Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review.
Tsutsumi Y, Kamiishi T, Kikuchi R, Ito S, Matsuoka S, Teshima T.
Hematol Oncol Stem Cell Ther. 2017 May 18. pii: S1658-3876(17)30052-3. doi: 10.1016/j.hemonc.2017.04.001.
Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation.
Racke M K, Imitola J.
JAMA Neurol. 2017 Apr 1;74(4):392-394. doi: 10.1001/jamaneurol.2016.5925.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani M P, Muraro P A, Saccardi R, Mancardi G.
Mult Scler. 2017 Feb;23(2):201-204. doi: 10.1177/1352458516645670.
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Paolo A. Muraro, MD; Marcelo Pasquini, MD; Harold L. Atkins, MD; James D. Bowen, MD; Dominique Farge, MD; Athanasios Fassas, MD; Mark S. Freedman, MD; George E. Georges, MD; Francesca Gualandi, MD; Nelson Hamerschlak, MD; Eva Havrdova, MD; Vassilios K. Kimiskidis, MD; Tomas Kozak, MD; Giovanni L. Mancardi, MD; Luca Massacesi, MD; Daniela A. Moraes, MD; Richard A. Nash, MD; Steven Pavletic, MD; Jian Ouyang, MD; Montserrat Rovira, MD; Albert Saiz, MD; Belinda Simoes, MD; Marek Trneny, MD; Lin Zhu, MD; Manuela Badoglio, MSc; Xiaobo Zhong, MS; Maria Pia Sormani, PhD; Riccardo Saccardi, MD; for the Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group
JAMA Neurol. Published online February 20, 2017. doi:10.1001/jamaneurol.2016.5867
Autologous hematopoietic cell transplantation in multiple sclerosis.
Bell S M, Sharrack B, Snowden J A.
Expert Opin Biol Ther. 2017 Jan;17(1):77-86.
2016
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL, Bowman M, Allan D, Anstee G, Arnold D L, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O’Connor P, Ramsay T, Sabloff M, Walker L, Freedman M S.
Lancet. 2016 Aug 6;388(10044):576-85. doi: 10.1016/S0140-6736(16)30169-6.
Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.
Brändle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M, Olsson T, Tumani H, Kristoferitsch W, Lottspeich F, Wekerle H, Hohlfeld R, Dornmair K.
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7864-9. doi: 10.1073/pnas.1522730113.
Antibodies in multiple sclerosis oligoclonal bands target debris.
Winger RC, Zamvil S S.
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7696-8. doi: 10.1073/pnas.1609246113.
Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation.
Bryant A, Atkins H, Pringle C E, Allan D, Anstee G, Bence-Bruckler I, Hamelin L, Hodgins M, Hopkins H, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J, Bredeson C.
JAMA Neurol. 2016 Jun 1;73(6):652-8. doi: 10.1001/jamaneurol.2016.0113
2015
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A, Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A, Amato MP, Massacesi L, Di Gioia M, Vuolo L, Currò D, Roccatagliata L, Filippi M, Aguglia U, Iacopino P, Farge D, Saccardi R; ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT); ASTIMS Haemato-Neurological Collaborative Group On behalf of the Autoimmune Disease Working Party ADWP of the European Group for Blood and Marrow Transplantation EBMT.
Neurology. 2015 Mar 10;84(10):981-8. doi: 10.1212/WNL.0000000000001329.
Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party.
Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, Hagglund H, Krasulova E, Simões BP, Carlson K, Pohlreich D, Labopin M, Saccardi R, Comi G, Mancardi GL, Bacigalupo A, Ciceri F, Farge D.
Mult Scler. 2015 Feb;21(2):189-97. doi: 10.1177/1352458514541978.
Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts
de Oliveira G, de Lima K, Colombini A, Pinheiro D, Panepucci R, Palma P, Brum D, Covas D, Simões B, de Oliveira MC, Donadi E, Malmegrim K
Cell Transplant. 2015;24(2):151-65.doi: 10.3727/096368913X675142. Epub 2013 Nov 20.
2014
Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP.
Press R, Askmark H, Svenningsson A, Andersen O, Axelson HW, Strömberg U, Wahlin A, Isaksson C, Johansson J E, Hägglund H.
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):618-24
2012
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.
Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, Kraft G, Mancardi GL, Nash R, Pasquini M, Martin R, Muraro PA; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group.
Mult Scler. 2012 Jun;18(6):825-34. doi: 10.1177/1352458512438454.
Autologous hematopoietic stem cell transplantation for multiple sclerosis–if confused or hesitant, remember: ‘treat with standard immune suppressive drugs and if no inflammation, no response.
Burt R K, Balabanov R, Voltarelli J, Barreira A, Burman J.
Mult Scler. 2012 Jun;18(6):772-5. doi: 10.1177/1352458512442993.
2010
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.
Pasquini M C, Griffith L M, Arnold D L, Atkins H L, Bowen J D, Chen J T, Freedman M S, Kraft G H, Mancardi G L, Martin R, Muraro P A, Nash R A, Racke M K, Storek J, Saccardi R.
Biol Blood Marrow Transplant. 2010 Aug;16(8):1076-83. doi: 10.1016/j.bbmt.2010.03.012.
New onset of myasthenia gravis after treatment of systemic sclerosis by autologous hematopoietic stem cell transplantation: sustained autoimmunity or inadequate reset of tolerance?
Deligny C, Clave E, Sibon D, Daikeler T, Keshmandt H, Carmagnat M, Douay C, Arfi S, Clair B, Toubert A, Farge D.
Hum Immunol. 2010 Apr;71(4):363-5. doi: 10.1016/j.humimm.2010.01.013.
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.
Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R, Akehurst R, Snowden J.
Bone Marrow Transplant. 2010 Jun;45(6):1014-21. doi: 10.1038/bmt.2009.305.
2008
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment .
Mazzanti B, Aldinucci A, Biagioli T, Barilaro A, Urbani S, Dal Pozzo S, Amato MP, Siracusa G, Crescioli C, Manuelli C, Bosi A, Saccardi R, Massacesi L, Ballerini C.
J Neuroimmunol. 2008 Aug 13;199(1-2):142-50.doi: 10.1016/j.jneuroim.2008.05.006. Epub 2008 Jun 17.
Autologous haematopoietic stem-cell transplantation in multiple sclerosis.
Mancardi G, Saccardi R.
Lancet Neurol. 2008 Jul;7(7):626-36. doi: 10.1016/S1474-4422(08)70138-8.
Immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis.
Créange A, Farge-Bancel D.
Rev Neurol (Paris). 2008 Mar;164(3):207-15. doi: 10.1016/j.neurol.2007.10.001.
2004
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.
Saccardi R, Tyndall A, Coghlan P, Denton C, Edan G, Emdin M, Farge D et al.
Bone Marrow Transplant. 2004 Nov;34(10):877-81.